miércoles, 4 de abril de 2012

Drug Patch Approved for Advanced Parkinson's and Restless Leg Syndrome: MedlinePlus

Drug Patch Approved for Advanced Parkinson's and Restless Leg Syndrome: MedlinePlus


Drug Patch Approved for Advanced Parkinson's and Restless Leg Syndrome

Neupro thought to stimulate brain receptors governing movement
URL of this page: http://www.nlm.nih.gov/medlineplus/news/fullstory_123679.html
 (*this news item will not be available after 07/02/2012)

By Scott Roberts
Tuesday, April 3, 2012HealthDay Logo
Related MedlinePlus Pages
TUESDAY, April 3 (HealthDay News) -- The Neupro (rotigotine) transdermal system has been approved by the U.S. Food and Drug Administration to treat advanced Parkinson's disease and moderate-to-severe restless leg syndrome, the Belgian drug maker UCB said Tuesday in a news release.
The continuous drug delivery patch was first approved by the FDA in 2007 to treat early-stage Parkinson's.
The dopamine agonist skin patch is believed to work by stimulating dopamine receptors within the caudate-putamen, the portion of the brain that regulates movement, the company said.
In clinical testing, observed side effects of Neupro included nausea, vomiting, skin site reactions, dizziness, insomnia and headache.
Neupro contains sodium metabisulfite, which could cause deadly allergic-like reactions in certain susceptible people. Also, the drug should not be used by pregnant women, UCB warned.

HealthDay
More Health News on:
Medicines
Parkinson's Disease
Restless Legs

No hay comentarios:

Publicar un comentario